Global Search

Hide Filters

Showing 1672 results

Press release / May 17, 2016

Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis

Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the…
Press release / Jun 26, 2018

Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
Ad hoc release / Mar 12, 2018

Novartis announces changes to the Executive Committee to support strategic priorities

Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
Press release / Jan 05, 2016

Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD

The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
Press release / May 11, 2017

Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities

Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
Press release / Sep 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
Press release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life…
Press release / Jan 28, 2015

Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera

Jakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
Press release / Feb 25, 2020

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
Press release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

The agreement includes two clinical stage molecules for schizophrenia and movement disorders and MIJ821, a clinical stage molecule previously licensed exclusively by Novartis for addressing treatment…